Form 4: Amgen Executive Murdo Gordon Reports Stock Disposal to Cover Tax Obligations

Murdo Gordon, EVP at Amgen, disposed of 753 shares of common stock on April 30, 2024, to satisfy tax withholding obligations related to vested Restricted Stock Units.

Summary

• On April 30, 2024, Murdo Gordon, an Executive Vice President at Amgen Inc., disposed of 753 shares of Amgen's common stock.
• The transaction was executed at a price of $276.38 per share.
• This disposal was to cover tax obligations related to the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Gordon directly owns 50,568 shares of Amgen common stock, which includes unvested RSUs and dividend equivalents.
• The RSUs will vest at various dates in the future, with the final vesting date being May 2, 2027.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing reflects a routine transaction related to executive compensation and tax obligations.

Future Outlook

The reporting person holds unvested RSUs that will vest over the next several years, indicating continued alignment with the company's long-term performance.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. This filing indicates that an executive is managing their tax obligations related to equity compensation.

Comparison to Industry Standards

• Executive compensation packages at large pharmaceutical companies like Amgen typically include a mix of salary, bonus, stock options, and restricted stock units.
• The vesting schedules for RSUs are generally structured to incentivize long-term performance and retention, often vesting over a period of 3-5 years.
• Similar to executives at companies like Johnson & Johnson and Pfizer, Amgen executives are required to disclose transactions in company stock to ensure transparency and prevent insider trading.

Key Dates